Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline Review, H2 2016 - Research and Markets

Research and Markets
Posted on: 25 Aug 16

Research and Markets has announced the addition of the "Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2016" drug pipelines to their offering.

This report provides comprehensive information on the therapeutic development for Cognitive Impairment Associated With Schizophrenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment Associated With Schizophrenia and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Cognitive Impairment Associated With Schizophrenia Overview
  3. Therapeutics Development
  4. Pipeline Products for Cognitive Impairment Associated With Schizophrenia - Overview
  5. Pipeline Products for Cognitive Impairment Associated With Schizophrenia - Comparative Analysis
  6. Cognitive Impairment Associated With Schizophrenia - Therapeutics under Development by Companies
  7. Cognitive Impairment Associated With Schizophrenia - Therapeutics under Investigation by Universities/Institutes
  8. Cognitive Impairment Associated With Schizophrenia Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Cognitive Impairment Associated With Schizophrenia - Products under Development by Companies
  13. Cognitive Impairment Associated With Schizophrenia - Products under Investigation by Universities/Institutes
  14. Cognitive Impairment Associated With Schizophrenia - Companies Involved in Therapeutics Development
  • AbbVie Inc.
  • Amarantus Bioscience Holdings, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bristol-Myers Squibb Company
  • Coronis Partners Ltd.
  • Eli Lilly and Company
  • FORUM Pharmaceuticals Inc.
  • H. Lundbeck A/S
  • Intra-Cellular Therapies, Inc.
  • Iproteos S.L.

For more information about this drug pipelines visit http://www.researchandmarkets.com/research/jf4fpc/cognitive

Related Topics: Central Nervous System Drugs, Mental Disorders Drugs, Schizophrenia Drugs

View source version on businesswire.com: http://www.businesswire.com/news/home/20160825005903/en/

Business Wire
www.businesswire.com

Last updated on: 25/08/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.